Solid solution compositions and use in chronic inflammation
The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
1. A solid solution pharmaceutical composition comprising:
a) 25% to 31% by weight of a propionic acid derived non-steroidal anti-inflammatory drug (NSAID);
b) 34% to 40% by weight of a hard fat that includes a triglyceride mixture;
c) 22% to 28% by weight of a liquid lipid mixture that includes a monoglyceride; and
d) 7% to 13% by weight of a liquid glycol polymer.
2. The solid solution pharmaceutical composition according to claim 1 , wherein the propionic acid derived NSAID is a Dexibuprofen, a Dexketoprofen, a Fenoprofen, a Flurbiprofen, an Ibuprofen, a Ketoprofen, a Loxoprofen, a Naproxen or an Oxaprozin.
3. The solid solution pharmaceutical composition according to claim 1 , wherein the pharmaceutical composition is liquid at normal human body temperature and is a solid at room temperature.
4. The solid solution pharmaceutical composition according to claim 1 , wherein the propionic acid derived NSAID is in an amount of 26% to 30% by weight.
5. The solid solution pharmaceutical composition according to claim 4 , wherein the propionic acid derived NSAID is in an amount of 27% to 29% by weight.
6. The solid solution pharmaceutical composition according to claim 1 , wherein the triglyceride mixture comprises a mixture of saturated C 10 -C 18 triglycerides having a melting point of between 41° C. to 45° C.
7. The solid solution pharmaceutical composition according to claim 1 , wherein the hard fat that includes a triglyceride mixture is in an amount of 35% to 39% by weight.
8. The solid solution pharmaceutical composition according to claim 7 , wherein the hard fat that includes a triglyceride mixture is in an amount of 36% to 38% by weight.
9. The solid solution pharmaceutical composition according to claim 1 , wherein the monoglyceride comprises a glycerol monomyristoleate, a glycerol monopalmitoleate, a glycerol monosapienate, a glycerol monooleate, a glycerol monoelaidate, a glycerol monovaccenate, a glycerol monolinoleate, a glycerol monolinoelaidate, a glycerol monolinolenate, a glycerol monostearidonate, a glycerol monoeicosenoate, a glycerol monomeadate, a glycerol monoarachidonate, a glycerol monoeicosapentaenoate, a glycerol monoerucate, a glycerol monodocosahexaenoate, a glycerol mononervonate, a glyceryl dibehenate, a glycerol behenate, a glycerol dipalmitostearate, a glycerol distearate, a glycerol monolinoleate, or any combination thereof.
10. The solid solution pharmaceutical composition according to claim 1 , wherein the monoglyceride comprises a glycerol monolinoleate.
11. The solid solution pharmaceutical composition according to claim 1 , wherein the liquid lipid mixture that includes a monoglyceride is in an amount of 23% to 27%.
12. The solid solution pharmaceutical composition according to claim 11 , wherein the liquid lipid mixture that includes a monoglyceride is in an amount of 24% to 26%.
13. The solid solution pharmaceutical composition according to claim 1 , wherein the liquid glycol polymer is a polyethylene glycol polymer, a liquid polypropylene glycol polymer, or both.
14. The solid solution pharmaceutical composition according to claim 1 , wherein the polyethylene glycol polymer comprises PEG 100, PEG 200, PEG 300, PEG 400, PEG 500, PEG 600, PEG 700, PEG 800, PEG 900, PEG 1000, or any combination thereof.
15. The solid solution pharmaceutical composition according to claim 1 , wherein the liquid glycol polymer is in an amount of 8% to 12% by weight.
16. The pharmaceutical composition according to claim 15 , wherein the liquid glycol polymer is in an amount of 9% to 11% by weight.
17. A solid solution pharmaceutical composition comprising:
a) 26% to 30% by weight of a propionic acid derived non-steroidal anti-inflammatory drug (NSAID);
b) 35% to 39% by weight of a hard fat that includes a triglyceride mixture;
c) 23% to 27% by weight of a liquid glyceride lipid that includes a monoglyceride; and
d) 8% to 12% by weight of a liquid glycol polymer.
18. The solid solution pharmaceutical composition according to claim 17 , wherein the pharmaceutical composition comprises:
a) 26% to 30% by weight of an ibuprofen
b) 35% to 39% by weight of a hard fat that includes a triglyceride mixture having a melting point of between 42° C. to 44° C. and comprises a mixture of saturated C 10 -C 18 triglycerides;
c) 23% to 27% by weight of a liquid lipid mixture that includes a glycerol monolinoleate; and
d) 8% to 12% by weight of a liquid polyethylene glycol polymer having a weight between 100g/mol to 1000 g/mol.
19. A solid solution pharmaceutical composition comprising:
a) 27% to 29% by weight of a propionic acid derived non-steroidal anti-inflammatory drug (NSAID);
b) 36% to 38% by weight of a hard fat that includes a triglyceride mixture;
c) 24% to 26% by weight of a liquid lipid mixture that includes a monoglyceride; and
d) 9% to 11% by weight of a liquid glycol polymer.
20. The solid solution pharmaceutical composition according to claim 19 , wherein the pharmaceutical composition comprises:
a) 27% to 29% by weight of an ibuprofen;
b) 36% to 38% by weight of a hard fat that includes a triglyceride mixture having a melting point of between 42° C. to 44° C. and comprises a mixture of saturated C 10 -C 18 triglycerides;
c) 24% to 26% by weight of a liquid lipid mixture that includes a glycerol monolinoleate; and
d) 9% to 11% by weight of a liquid polyethylene glycol polymer having a weight between 100g/mol to 1000 g/mol.